Ability of Mayo Clinic HPLC Method to Measure Fecal Bile Acids

Overview

Información sobre este estudio

The investigators' hypothesis is that therapy with Colesevelam, reduces fecal bile acid excretion in patients with IBS-diarrhea with prior evidence of increased fecal 48 hour total bile acid excretion. The investigators aim to study the ability of the HPLC assay for fecal bile acids to demonstrate responsiveness after treatment with Colesevelam.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Patients with IBS-diarrhea with prior evidence of increased fecal 48 hour total bile acid and increased fasting serum 7alphaC4 who meet the following:

INCLUSION CRITERIA

  • BDQ- IBS symptoms: Positive by Rome lll criteria
  • HAD: No restrictions on Hospital Anxiety/Depression score.
  • Age: 18-65 years
  • Gender: Men or women. Women of childbearing potential will have a negative pregnancy test before initiation of medication.

EXCLUSION CRITERIA

  • Use of drugs or agents within the past 1 week or planned use in the subsequent 2 weeks during the study period (Birth control pill, estrogen replacement therapy, and thyroxine replacement are permissible exceptions):
    • Agents that alter GI transit including opioids, narcotics, anticholinergics, tricyclic antidepressants, SNRI antidepressants.
    • Analgesic drugs including opiates, NSAID, COX 2 inhibitors
    • Intake of medication that could interfere with the interpretation of the study.
  • Female subjects who are pregnant or breast-feeding. Females must be either surgically sterilized, postmenopausal (>12 months since last menses), or, if of childbearing potential, using reliable methods of contraception as determined by the physician.
  • Abdominal surgery (except Appendectomy)
  • Patients with known chronic liver disease or history of elevated AST/ALT 2.0 X upper limit of normal.
    • BA synthesis and possible false positive or negative fecal bile acid or serum 7alphaC4 result. If there is no AST or ALT values in the medical record, the study physicians will determine if the tests need to be run.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus

Rochester, Minn.

Investigador principal de Mayo Clinic

Michael Camilleri, M.D.

Cerrado para la inscripción

More information

Publicaciones

Publications are currently not available
.
CLS-20111687

Mayo Clinic Footer